<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393688</url>
  </required_header>
  <id_info>
    <org_study_id>BM-821</org_study_id>
    <nct_id>NCT04393688</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV Fistula</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Tri-wire Balloon Dilatation Catheter for the Treatment of Dysfunctional AV Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrosMed Medical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCRF Inc., Beijing, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BrosMed Medical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicenter, randomized, controlled study is designed to evaluate the
      safety and effectiveness of the Tri-wire Peripheral Balloon Dilatation Catheter compared to a
      standard PTA Catheter in treating subjects presenting with clinical and hemodynamic
      abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 25, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Right after operation</time_frame>
    <description>The target lesion residual stenosis＜30%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Right after operation</time_frame>
    <description>During the operation, Balloon dilatation catheters can be delivered to the target lesion, inflated≤RBP without rupture and withdrawed successfully</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>12-48 hours</time_frame>
    <description>Base on the technical success, without MAE including death, thrombosis, allergic reactions, pulmonary diseases (pulmonary edema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilating Pressure</measure>
    <time_frame>During the operation</time_frame>
    <description>The minimum pressure with which the balloon can be completely inflated without waist during the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Right after operation</time_frame>
    <description>The pain during dilating procedure, measured by NRS (increase from 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Primary Patency (TLPP)</measure>
    <time_frame>1 month</time_frame>
    <description>Defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis. TLPP ends with a clinically driven re-intervention of the target lesion or access thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion restenosis</measure>
    <time_frame>1 month</time_frame>
    <description>Target lesion diameter restenosis rate（measured by DUS）=100%*(1-(MLD/RVD)) (MLD includes 5mm range of proximal and distal of targer lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fistula Blood Flow</measure>
    <time_frame>1 month</time_frame>
    <description>Measured Brachial artery blood flow of arteriovenous fistula flow assessed by DUS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>Number of device and procedure related adverse events (CEC Adjudicated)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Experimental: Tri-wire Peripheral Balloon Dilatation Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous transluminal angiography (PTA) will be performed using the Tri-wire Peripheral Balloon Dilatation Catheter. Interventions: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter; Procedure: Percutaneous Transluminal Angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous transluminal angiography (PTA) will be performed using OHICHO Ⅱ PTA Balloon Catheter, a commercially available high-pressure PTA balloon. Multiple balloons, inflations and/or prolonged inflation may be used. Interventions: Device: OHICHO Ⅱ PTA Balloon Catheter. Procedure: Percutaneous Transluminal Angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter</intervention_name>
    <description>Procedure:
Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
    <arm_group_label>Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.</arm_group_label>
    <arm_group_label>Experimental: Tri-wire Peripheral Balloon Dilatation Catheter</arm_group_label>
    <other_name>Device: OHICHO Ⅱ PTA Balloon Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥18 years;

          2. Able to understand the purpose of the study, willing to participate and sign the
             informed consent, able and willing to accept the follow-up;

          3. Indications of percutaneous transluminal angioplasty for target lesion: target lesion
             shows &gt;50% narrowing relative to adjacent normal vein diameter by angiography or
             ultrasound with one of the indicators listed in KDOQI vascular access guideline 2019
             update Table 13.2.

          4. Reference vessel diameter of target lesion from 3.0 mm to 8.0 mm.

          5. Target lesion located from proximal to the anastomosis to the reflux vein at the
             distal end of the subclavian vein.

          6. De novo or restenosis lesion.

          7. Single or tandem lesion, length of which ≤ 60mm.

        Exclusion Criteria:

          1. Women who are pregnant, nursing, or planning to become pregnant during the study.

          2. Patients who have accepted major surgeries within 30 days prior to the enrollment.
             (such as thoracic surgery, cranial surgery).

          3. Patients who plan to accept major surgeries within 30 days after the enrollment. (such
             as thoracic surgery, cranial surgery).

          4. Occlusion lesion or thrombosis.

          5. Infected fistula or severe systemic infection.

          6. Patients who suffer from central venous diseases.

          7. Patients known to be allergic or contraindicated to contrast agents.

          8. Patients who have participated in another clinical trial within 3 months prior to the
             study, or previous enrollment in this study.

          9. Subject has another medical condition, which, in the opinion of the Investigator, may
             cause him/her to be noncompliant with the protocol or confound the data
             interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qizhuang Jin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qizhuang Jin</last_name>
    <phone>13301011122</phone>
    <email>jinqizhuang@bjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanqi Yin</last_name>
    <phone>13810454638</phone>
    <email>thomasyq135@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qizhuang Jin</last_name>
      <phone>13301011122</phone>
      <email>jinqizhuang@bjmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yanqi Yin</last_name>
      <phone>13810454638</phone>
      <email>thomasyq135@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhengya Yu</last_name>
      <phone>13910011332</phone>
      <email>zhengyayu_tr@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Chen</last_name>
      <phone>18101031315</phone>
      <email>william19830315@sohu.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bo Hu</last_name>
      <phone>13760885770</phone>
      <email>hubo26@foxmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zongchao Yu</last_name>
      <phone>13247362204</phone>
      <email>709401195@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Pei Wang</last_name>
      <phone>13523467291</phone>
      <email>wangpei146@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xianhui Liang</last_name>
      <phone>13949002155</phone>
      <email>liangxianhui1776@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junwei Yang</last_name>
      <phone>18951767513</phone>
      <email>jwyang@njmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hong Ye</last_name>
      <phone>13082552804</phone>
      <email>yehong@njmu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yaxue Shi</last_name>
      <phone>13918331840</phone>
      <email>drshiyaxue@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xuedong Bao</last_name>
      <phone>18717797712</phone>
      <email>baoxuedong6413@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhengjiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hua Li</last_name>
      <phone>13588706757</phone>
      <email>lihua@srrsh.com</email>
    </contact>
    <contact_backup>
      <last_name>Xuan Zheng</last_name>
      <phone>13675891157</phone>
      <email>349454663@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

